SLC7A11 inhibitors such as sulfasalazine and sorafenib, as well as other ferroptosis inducers, are currently being tested in combination therapy with cisplatin and doxorubicin in clinical trials for head and neck carcinomas, acute myeloid leukemia, glioblastoma, ovarian cancer, hepatocellular carcinoma and renal cell carcinoma (47,55). Here, SLC7A11 is linked to ovarian cancer.